Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
CNS Neuroscience & Therapeutics · 2023-09 · 29 (9) · 2705-2716
DOI: 10.1111/cns.14215 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 10.04.2023. Verfasst von Yamin Shu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antipsychotic Agents, Bipolar Disorder. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objective
Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine‐associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS).
Methods
Reporting odds ratio (ROR) was used to quantify the signals of quetiapine‐related cardiac AEs from the first quarter (Q1) of 2018–2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale.
Results
A total of 1004 cases of quetiapine‐associated cardiac AEs were identified, with 31 signals being detected, among which 13 AEs were identified as new and unexpected signals. Besides, nine and 22 cardiac AEs were identified as moderate and weak clinical priority. The median TTO for moderate and weak clinical priority signals were 0 and 4 days, respectively. All of the cardiac AEs had early failure type characteristics, suggesting that most of the patients developed cardiac AEs in a few days after quetiapine treatment, and that the risk of cardiac AEs occurrence would be gradually decreased over time.
Conclusion
Our study provided valuable evidence for health‐care professionals to mitigate the risk of quetiapine‐associated cardiac AEs based on an extensive analysis of a real‐world, large‐sample FAERS database, and prioritize cardiac AE signals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Qilin Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shu, Y., Ding, Y., Liu, L., & Zhang, Q. (2023). Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. CNS Neuroscience & Therapeutics, 29(9), 2705-2716. https://doi.org/10.1111/cns.14215
Vancouver
Shu Y, Ding Y, Liu L, Zhang Q. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. CNS Neuroscience & Therapeutics. 2023;29(9):2705-2716. doi:10.1111/cns.14215
BibTeX
@article{Shu2023,
author = {Shu, Yamin and Ding, Yiling and Liu, Lulu and Zhang, Qilin},
title = {Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
volume = {29},
number = {9},
pages = {2705--2716},
doi = {10.1111/cns.14215}
}
EUVIMED